Spravato
Spravato
SPRAVATO® (esketamine) CIII Nasal Spray is the only FDA-approved treatment used as monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
SPRAVATO® Treatment at Sage Elevate
Sage Elevate partners with referring providers to deliver safe, efficient, and patient-centered SPRAVATO® (esketamine) treatment for individuals with treatment-resistant depression. Our coordinated care model offers two flexible referral pathways while ensuring exceptional clinical oversight and patient experience.
Pathway 1: Full Clinical Management by Sage Elevate
Our experienced clinical team will:
- Evaluate your patient for SPRAVATO® eligibility
- Determine appropriate dosing
- Manage and monitor ongoing SPRAVATO® treatment
This option allows you to refer with confidence while Sage Elevate oversees all aspects of care delivery.
Pathway 2: Prescriber-Directed Administration
Prefer to remain the prescribing provider?
- Submit SPRAVATO® order form along with all relevant clinical notes.
- Our clinicians will administer treatment and monitor the patient on your behalf
This option offers continuity with your treatment plan while leveraging our specialized treatment setting and staff.
Why Partner with Sage Elevate?
Sage Elevate removes logistical barriers and collaborates closely with your office—so you can focus on overall care while your patient receives SPRAVATO® treatments. Both referral pathways include:
- Best-in-class, coordinated care model
- Treatment in a REMS-certified, serene, spa-like facility
- Highly trained clinical staff dedicated to patient safety and comfort, including Nurse Practitioners on-site.
- Detailed treatment note delivered within 24 hours
Administration Information
To ensure safe and appropriate use, SPRAVATO® nasal spray is administered only at REMS-certified treatment centers
After taking SPRAVATO®, patients are monitored and evaluated by a healthcare provider for at least 2 hours until patients are safe to leave
Treatment involves multiple sessions, with the frequency and duration varying depending on the individual patient's needs and the specific indication.
Once per week or every 2 weeks
Potential Side Effects
SPRAVATO® may cause increased blood pressure, sedation or loss of consciousness. In some cases, patients may display diminished or less apparent breathing. Other side effects may occur.
See a full list of serious side effects on the drug manufacturer website.
Before you attend your first appointment at Sage Elevate, please make sure to review the documents below. The Behavioral Health Consent Form, Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the other forms are for reference only. Please contact us if you have any questions.
